UroGen Pharma Ltd. provided revenue guidance for the full year 2022. for the year, the company expects net product revenues from Jelmyto to be in the range of $70 to $80 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.4 USD | +3.83% | +2.78% | -11.13% |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
May. 13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.13% | 466M | |
+7.71% | 115B | |
+12.82% | 107B | |
-13.43% | 22.31B | |
-3.99% | 21.6B | |
-6.59% | 18.23B | |
-39.93% | 17.62B | |
+6.82% | 14.26B | |
+33.08% | 12.37B | |
-27.77% | 8.28B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma Ltd. Provides Revenue Guidance for the Full Year 2022